| COVID-19 pandemic support programs for healthcare workers and implications for occupational mental health: a narrative review E David, JM DePierro, DB Marin, V Sharma, DS Charney, CL Katz Psychiatric Quarterly, 1-21, 2021 | 62 | 2021 |
| Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study AD Pagan, E David, B Ungar, S Ghalili, H He, E Guttman-Yassky The Journal of Allergy and Clinical Immunology: In Practice 10 (9), 2378-2385, 2022 | 26 | 2022 |
| The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective E David, B Ungar, Y Renert‐Yuval, P Facheris, E Del Duca, ... Clinical & Experimental Allergy, 2023 | 18 | 2023 |
| Herpes zoster following COVID-19 vaccination. E David, A Landriscina Journal of Drugs in Dermatology: JDD 20 (8), 898-900, 2021 | 18 | 2021 |
| The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis B Ungar, L Lavin, AK Golant, A Gontzes, E David, YD Estrada, GK Singer, ... Annals of Allergy, Asthma & Immunology 128 (6), 734-736, 2022 | 11 | 2022 |
| Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape‐strips and biopsies E Del Duca, H He, Y Liu, AD Pagan, E David, J Cheng, B Carroll, ... Allergy 79 (1), 80-92, 2024 | 7 | 2024 |
| Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis E Guttman-Yassky, P Facheris, JC Da Rosa, C Rothenberg-Lausell, ... Journal of Allergy and Clinical Immunology 152 (4), 916-926, 2023 | 7 | 2023 |
| 299 Oral difelikefalin improves itch and inflammatory biomarkers in atopic dermatitis subjects with moderate-to-severe pruritus E Guttman-Yassky, P Facheris, JC Da Rosa, E Del Duca, Y Estrada, ... Journal of Investigative Dermatology 142 (8), S51, 2022 | 2 | 2022 |
| 140 Chronic hand eczema shares a common molecular signature regardless of atopic dermatitis status J Bar, E Del Duca, E David, P Brunner, R Bissonnette, E Guttman-Yassky Journal of Investigative Dermatology 143 (11), S356, 2023 | 1 | 2023 |
| Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling K Hawkins, E David, JW Glickman, E Del Duca, E Guttman-Yassky, ... Expert Review of Clinical Immunology, 1-6, 2024 | | 2024 |
| IL-12/23-targeting in seborrheic dermatitis patients leads to long-lasting response S Ghalili, E David, B Ungar, K Tan, CCV Lang, M Meariman, E Andrews, ... Archives of Dermatological Research 315 (10), 2937-2940, 2023 | | 2023 |
| Online attitudes about the first approved systemic treatment for alopecia areata: a sentiment analysis of Reddit posts E David, R O’Hagan, B Ungar Clinical and Experimental Dermatology 48 (12), 1369-1370, 2023 | | 2023 |
| 231 Non-lesional type 2 and type 17/22 immune activation precedes lesional type 1-associated inflammation in skin of vitiligo patients PM Brunner, E Del Duca, M Manson, J Gay-Mimbrera, P Gómez-Arias, ... Journal of Investigative Dermatology 143 (11), S371, 2023 | | 2023 |
| The pathogenetic role of Th17 immune response in atopic dermatitis E David, T Czarnowicki Current Opinion in Allergy and Clinical Immunology 23 (5), 446-453, 2023 | | 2023 |
| Individual and sociodemographic factors associated with polysensitization at a New York City hospital S Ghalili, M Downes, R O'Hagan, S Owji, E David, SA Caldas, ... Annals of Allergy, Asthma & Immunology 131 (3), 388-391, 2023 | | 2023 |
| Oral difelikefalin improves itch and inflammatory biomarkers in subjects with atopic dermatitis with moderate-to-severe pruritus E Guttman-Yassky, P Facheris, JC Da Rosa, Y Estrada, E David, A Pavel, ... BRITISH JOURNAL OF DERMATOLOGY 187 (3), E116-E116, 2022 | | 2022 |
